8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A critical analysis of SURMOUNT-3's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for tirzepatide after intensive lifestyle intervention.
A deep-dive into the SURMOUNT-3 trial design, randomization strategy, estimand framework, and statistical choices that shaped the tirzepatide-after-lifestyle results.
Health-economic analyses of SURMOUNT-3: cost per QALY for tirzepatide after intensive lifestyle intervention, payer-coverage barriers, list-price vs net-price gaps, and value considerations for patients and clinicians.
Analysis of SURMOUNT-3 long-term follow-up, weight regain patterns after tirzepatide discontinuation, durability of cardiometabolic benefits, and what the trial's design tells us about sustained obesity treatment.
Detailed breakdown of the SURMOUNT-3 trial results for tirzepatide after intensive lifestyle intervention, including effect sizes, confidence intervals, secondary endpoints, and response distribution.
Detailed breakdown of SURMOUNT-3 pre-specified and post-hoc subgroup analyses examining tirzepatide response by age, sex, BMI, race/ethnicity, and baseline biomarkers.
A plain-English deep dive into the SURMOUNT-3 trial, which tested whether tirzepatide adds meaningful weight loss on top of an intensive lifestyle program in adults with obesity.
A clinical-practice analysis of the SURMOUNT-3 trial: how tirzepatide after intensive lifestyle intervention reshapes prescribing sequences, guideline updates, and patient selection for GLP-1 therapy.